A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513445-37-00

Enrollment

Registered

2026-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

previously untreated RT, irrespective of risk factors and disease stage

Brief summary

Investigator-assessed progression-free survival (PFS) according to Lugano criteria

Detailed description

Overall response rate (ORR; assessed by Lugano), Complete response rate (CRR; assessed by Lugano guidelines) at the end of (combination) treatment [EO(C)T], Best response (assessed by Lugano), Undetectable minimal residual disease (uMRD) rate in peripheral blood at EO(C)T, Duration of response (DOR) according to Lugano criteria, Overall survival (OS), Time-to-next treatment (TTNT), Treatment-free survival (TFS), Proportion of patients receiving allogeneic stem cell transplantation (SCT) for consolidation

Interventions

DRUGCaelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion

DRUGJaypirca 100 mg film-coated tablets

DRUGEPCORITAMAB

DRUGPREDNISOLONE

DRUGVINCRISTINE

DRUGCYCLOPHOSPHAMIDE

DRUGMabThera 100 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Investigator-assessed progression-free survival (PFS) according to Lugano criteria	—

Secondary

Measure	Time frame
Overall response rate (ORR; assessed by Lugano), Complete response rate (CRR; assessed by Lugano guidelines) at the end of (combination) treatment [EO(C)T], Best response (assessed by Lugano), Undetectable minimal residual disease (uMRD) rate in peripheral blood at EO(C)T, Duration of response (DOR) according to Lugano criteria, Overall survival (OS), Time-to-next treatment (TTNT), Treatment-free survival (TFS), Proportion of patients receiving allogeneic stem cell transplantation (SCT) for consolidation	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 19, 2026